IL28B rs12979860 polymorphism and zinc supplementation affect treatment outcome and liver fibrosis after direct-acting antiviral hepatitis C therapy

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2090-5920
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
IL28B rs12979860 polymorphism and zinc supplementation affect treatment outcome and liver fibrosis after direct-acting antiviral hepatitis C therapy ; volume:19 ; number:1 ; day:8 ; month:10 ; year:2021 ; pages:1-10 ; date:12.2021
Journal of Genetic Engineering and Biotechnology ; 19, Heft 1 (8.10.2021), 1-10, 12.2021

Urheber
Attallah, Abdelfattah M.
Omran, Dalia
Abdelrazek, Mohamed A.
Hassany, Mohamed
Saif, Sameh
Farid, Aza
Essawey, Riham El
Ghaffar, Muhammad Abdel
Aabdelghany, Marwa
Yosry, Ayman
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s43141-021-00250-y
URN
urn:nbn:de:101:1-2021122507281223968960
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:22 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Attallah, Abdelfattah M.
  • Omran, Dalia
  • Abdelrazek, Mohamed A.
  • Hassany, Mohamed
  • Saif, Sameh
  • Farid, Aza
  • Essawey, Riham El
  • Ghaffar, Muhammad Abdel
  • Aabdelghany, Marwa
  • Yosry, Ayman
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Effect of immunogenetics polymorphism and expression on direct-acting antiviral drug response in chronic hepatitis C

Effect of immunogenetics polymorphism and expression on direct-acting antiviral drug response in chronic hepatitis C

Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use

Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era

Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis

Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis

Adoption of direct-acting antiviral medications for hepatitis C: a retrospective observational study

Adoption of direct-acting antiviral medications for hepatitis C: a retrospective observational study

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)

Acute reversible rhabdomyolysis during direct-acting antiviral hepatitis C virus treatment: a case report

Acute reversible rhabdomyolysis during direct-acting antiviral hepatitis C virus treatment: a case report

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

Direct-acting antiviral treatment downregulates immune checkpoint inhibitor expression in patients with chronic hepatitis C

Direct-acting antiviral treatment downregulates immune checkpoint inhibitor expression in patients with chronic hepatitis C

Perceived physical health outcomes of direct-acting antiviral treatment for hepatitis C: a qualitative study

Perceived physical health outcomes of direct-acting antiviral treatment for hepatitis C: a qualitative study

Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents

Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents

Hepatitis C in healthcare personnel: follow-up analysis of treatments with direct-acting antiviral agents

Hepatitis C in healthcare personnel: follow-up analysis of treatments with direct-acting antiviral agents

Verbundene Objekte